United Therapeutics Corporation
UTHR
$536.37
$0.250.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.61% | 13.50% | 17.62% | 19.85% | 23.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.61% | 13.50% | 17.62% | 19.85% | 23.63% |
| Cost of Revenue | 24.12% | 17.09% | 16.21% | 18.41% | 20.27% |
| Gross Profit | 8.98% | 13.06% | 17.80% | 20.03% | 24.04% |
| SG&A Expenses | 18.08% | 20.01% | 20.72% | 24.95% | 34.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.13% | 15.55% | 15.39% | 22.65% | 25.37% |
| Operating Income | 3.17% | 11.36% | 20.01% | 17.08% | 21.95% |
| Income Before Tax | 11.36% | 15.89% | 15.41% | 13.24% | 20.77% |
| Income Tax Expenses | 10.26% | 20.70% | 13.02% | 6.87% | 18.79% |
| Earnings from Continuing Operations | 11.68% | 14.47% | 16.15% | 15.25% | 21.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.68% | 14.47% | 16.15% | 15.25% | 21.35% |
| EBIT | 3.17% | 11.36% | 20.01% | 17.08% | 21.95% |
| EBITDA | 3.88% | 11.96% | 20.53% | 18.08% | 22.56% |
| EPS Basic | 14.09% | 17.16% | 19.89% | 21.16% | 25.66% |
| Normalized Basic EPS | 6.52% | 16.77% | 27.46% | 27.05% | 31.44% |
| EPS Diluted | 13.45% | 15.91% | 17.75% | 18.50% | 24.01% |
| Normalized Diluted EPS | 6.01% | 15.56% | 25.07% | 24.22% | 29.63% |
| Average Basic Shares Outstanding | -1.99% | -2.46% | -3.24% | -4.90% | -3.42% |
| Average Diluted Shares Outstanding | -1.44% | -1.28% | -1.37% | -2.77% | -2.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |